Skip to Main Content

Paper Details

Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Expert Opin Drug Metab Toxicol
10
2019
HGOS, gene variations, genes, germline polymorphisms, high-grade osteosarcoma, osteosarcoma, patients, polymorphisms, tumor, tumor cells
Author NameAffiliation
Claudia Maria Hattingera Pharmacogenomics and Pharmacogenetics Research Unit of the Laboratory of Experimental Oncology , IRCCS Istituto Ortopedico Rizzoli
Claudia Maria Hattingera Pharmacogenomics and Pharmacogenetics Research Unit of the Laboratory of Experimental Oncology , IRCCS Istituto Ortopedico Rizzoli
Piero PicciIRCCS Istituto Ortopedico Rizzoli
Piero PicciIRCCS Istituto Ortopedico Rizzoli
Massimo Serraa Pharmacogenomics and Pharmacogenetics Research Unit of the Laboratory of Experimental Oncology , IRCCS Istituto Ortopedico Rizzoli
Massimo Serraa Pharmacogenomics and Pharmacogenetics Research Unit of the Laboratory of Experimental Oncology , IRCCS Istituto Ortopedico Rizzoli
  • 1 - 6

Datasets

Release 1.2